Home NeoTract


NeoTract Designates Dr. Joshua Langston as UroLift® Center of Excellence

The designation recognizes that Dr. John Langston has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

NeoTract to Unveil New Clinical Data on the UroLift® System at American Urological Association 2018 Meeting

5/16/18: 1 Year Results from the study of UroLift System for the obstructive median lobe twill be presented as a late-breaking abstract.

Data from Large Real-World Study of UroLift® System, Confirming Positive Results for Company’s Treatment for Enlarged Prostate

3/19/18: Retrospective Study of Data from More than 800 Patients Consistent with Published, Controlled Clinical Studies.

NeoTract Announces Publication of Five-Year Results from Pivotal Trial of the UroLift® System

Treatment for BPH Now “Standard of Care” According to Study Investigators; Results Published in Canadian Journal of...

NeoTract Inc. Announces Cigna Coverage for the UroLift® System for Enlarged Prostate

Minimally Invasive Treatment Now Available to Millions More Men Across the United States NeoTract, Inc., a medical device...

NeoTract Inc. Announces Presentations of Multiple Clinical Studies Featuring Five-Year Data from Pivotal Randomized Trial of UroLift®

Announced at the American Urological Association 2017 Meeting NeoTract, Inc., a medical device company focused on addressing unmet...

NeoTract Inc. Receives #Gamechanger Award for Innovation

Innovation Tri-Valley Recognizes Businesses with Global Impact NeoTract, Inc., a medical device company focused on addressing unmet needs...

UroLift System for Enlarged Prostate Now Shown to be Durable Through Five Years: Results from Pivotal L.I.F.T. Randomized Study Presented

“The UroLift System is truly a new standard for the treatment of BPH. This conclusion of the landmark L.I.F.T. randomized clinical trial offers high-quality clinical data that demonstrate the durable benefits this unique treatment option can offer,” said Dr. Roehrborn.